A revenue-generating, small-cap Canadian pharmaceutical company
Revenue Projected at $150,000,000 by 2025
Message: INTERVIEW ALERT: Valeo Pharma (VPH: CSE) (VPHIF: OTCQB)
We just finished with CEO Steve Saviuk.
We discuss:
- Record '21 revenues of $13.6M up 81% vs. '20
- Q4-21: $3.4M up 53% over Q4-20
- 3 transformational products launched in '21
- Public reimbursement for asthma drugs
- +more
OUT TOMORROW
New Message
Please
login
to post a reply